Physician profile
Kathleen J Dass
NPI 1477849610
$446,288.03
in general payments reported to CMS, 2019-2025
32 companies · $58K in 2025
The $58K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $15K · 2021: $33K · 2022: $87K · 2023: $153K · 2024: $99K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $268K · Travel and Lodging: $18K · Food and Beverage: $14K · Consulting Fee: $9,190 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $268,325.05 |
| Travel and Lodging | $18,400.25 |
| Food and Beverage | $13,940.88 |
| Consulting Fee | $9,190.00 |
| Education | $206.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $133,133.38 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $133,043.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $91,725.79 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $47,530.95 | 2020-2025 | |
| Amgen INC. | $13,834.55 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $13,756.21 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $7,345.28 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,803.47 | 2020-2021 | |
| Csl Behring | $930.88 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $682.21 | 2020-2025 | Hyqvia, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.36 | 2020-2022 | |
| Pfizer INC. | $329.85 | 2019-2025 | |
| Grifols USA, LLC | $180.37 | 2023-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $177.32 | 2020-2024 | |
| Lilly USA, LLC | $171.74 | 2019-2025 | Ebglyss, Taltz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $148.66 | 2019 | |
| Novo Nordisk INC | $145.84 | 2020 | |
| Alk-Abello, INC | $125.07 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Leo Pharma INC. | $110.54 | 2022-2024 | Adbry |
| Galderma Laboratories, L.P. | $104.87 | 2024-2025 | Nemluvio |
| Blueprint Medicines Corporation | $80.80 | 2024-2025 | Ayvakit |
| Kaleo, INC. | $73.72 | 2022-2023 | Auvi-Q |
| Organon LLC | $73.53 | 2025 | Vtama |
| Pharming Healthcare, INC. | $68.98 | 2024-2025 | Ruconest |
| Optinose US, INC. | $54.74 | 2024 | |
| Greer Laboratories, INC. | $48.91 | 2024-2025 | Oralair, Palforzia |
| Paratek Pharmaceuticals, INC. | $47.80 | 2025 | Xhance |
| Abbvie INC. | $47.77 | 2022-2023 | Rinvoq |
| Biocryst US Sales Co., LLC | $27.17 | 2022 | |
| Phadia US INC. | $19.26 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.79 | 2021 | |
| Hikma Pharmaceuticals USA | $13.51 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Dass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.